Interferon Beta-1a/Albumin
Brand name: Rebif
Rank #223 of 500 drugs by total cost
$60.7M
Total Cost
5,917
Total Claims
$60.7M
Total Cost
373
Prescribers
$10K
Cost per Claim
0
Beneficiaries
6,028
30-Day Fills
$163K
Avg Cost/Provider
16
Avg Claims/Provider
About Interferon Beta-1a/Albumin
Interferon Beta-1a/Albumin (sold as Rebif) was prescribed 5,917 times by 373 Medicare Part D providers in 2023, costing the program $60.7M. At $10K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 220 | Buprenorphine (Buprenorphine) | $61.1M | 156,598 |
| 221 | Ferric Citrate (Auryxia) | $60.7M | 32,798 |
| 222 | Dextromethorphan Hbr/Quinidine (Nuedexta) | $60.7M | 60,863 |
| 223 | Interferon Beta-1a/Albumin (Rebif) | $60.7M | 5,917 |
| 224 | Sodium Zirconium Cyclosilicate (Lokelma) | $60.2M | 77,902 |
| 225 | Golimumab (Simponi Aria) | $59.9M | 8,718 |
| 226 | Olanzapine (Olanzapine) | $59.4M | 1,444,781 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology